Stopping rules for phase II studies
- 1 June 2001
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 51 (6) , 523-529
- https://doi.org/10.1046/j.0306-5251.2001.01381.x
Abstract
This paper, the second in a series of three papers concerned with the statistical aspects of interim analyses in clinical trials, is concerned with stopping rules in phase II clinical trials. Phase II trials are generally small‐scale studies, and may include one or more experimental treatments with or without a control. A common feature is that the results primarily determine the course of further clinical evaluation of a treatment rather than providing definitive evidence of treatment efficacy. This means that there is more flexibility available in the design and analysis of such studies than in phase III trials. This has led to a range of different approaches being taken to the statistical design of stopping rules for such trials. This paper briefly describes and compares the different approaches. In most cases the stopping rules can be described and implemented easily without knowledge of the detailed statistical and computational methods used to obtain the rules.Keywords
This publication has 28 references indexed in Scilit:
- Sequential designs for phase III clinical trials incorporating treatment selectionStatistics in Medicine, 2003
- Interim analyses and sequential designs in phase III studiesBritish Journal of Clinical Pharmacology, 2001
- Approximately optimal designs for phase II clinical studiesJournal of Biopharmaceutical Statistics, 1998
- Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic DesignsJournal of the American Statistical Association, 1994
- An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectivesControlled Clinical Trials, 1994
- A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluationStatistics in Medicine, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Sample sizes for phase II and phase III clinical trials: An integrated approachStatistics in Medicine, 1986
- Statistical considerations for pilot studiesInternational Journal of Radiation Oncology*Biology*Physics, 1980
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961